Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine.
Baculovirus
HPV
L1
Protein purification
Sf9
Vaccine
Journal
Archives of Razi Institute
ISSN: 2008-9872
Titre abrégé: Arch Razi Inst
Pays: Iran
ID NLM: 101549567
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
12
04
2023
accepted:
20
05
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Today, the human papillomavirus (HPV) L1 protein is the main target in the construction of prophylactic HPV vaccines. The production of virus-like particles (VLPs) that closely resemble the natural structure of the HPV16 virus and induce high levels of virus-neutralizing antibodies in animals and humans is facilitated by the expression of HPV16-L1 protein in eukaryotic cells. The Bac-to-Bac system has been previously used to produce high levels of recombinant proteins. In this study, we utilized this expression system to generate HPV16-L1 VLPs in
Identifiants
pubmed: 38028838
doi: 10.22092/ARI.2023.361975.2708
pii: ARI-78-3
pmc: PMC10657962
doi:
Substances chimiques
Vaccines, Virus-Like Particle
0
Recombinant Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
997-1003Déclaration de conflit d'intérêts
The authors declare that this research was conducted in the absence of any relationships that could be construed as a potential conflict of interest.
Références
Int J Cancer. 2021 Mar 1;148(5):1066-1076
pubmed: 32895947
Curr Probl Cancer. 2018 Sep;42(5):457-465
pubmed: 30064936
Methods. 2020 Aug 1;180:3-18
pubmed: 32534131
Middle East J Dig Dis. 2016 Oct;8(4):249-266
pubmed: 27957288
Hum Fertil (Camb). 2019 Jun;22(2):133-138
pubmed: 29688091
J Struct Biol X. 2019 Jan-Mar;1:100003
pubmed: 32337507
Biotechnol Adv. 2012 Sep-Oct;30(5):1102-7
pubmed: 21968145
PLoS One. 2015 Apr 23;10(4):e0123944
pubmed: 25905781
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):9068-9073
pubmed: 28784806
Front Genet. 2019 May 24;10:489
pubmed: 31231420
Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):529-32
pubmed: 17250423
NPJ Vaccines. 2020 Feb 14;5(1):14
pubmed: 32128255
Viruses. 2019 Feb 26;11(3):
pubmed: 30813511
BMC Infect Dis. 2017 Jul 18;17(1):502
pubmed: 28720082
Biotechnol J. 2015 May;10(5):702-14
pubmed: 25800821
Hum Vaccin. 2007 Jul-Aug;3(4):139-45
pubmed: 17581283
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
Clin Ther. 2014 Jan 1;36(1):24-37
pubmed: 24417783
BMC Biotechnol. 2019 Mar 29;19(1):20
pubmed: 30925874
PLoS One. 2014 Mar 11;9(3):e90912
pubmed: 24618636
Int J Mol Sci. 2019 Sep 09;20(18):
pubmed: 31505747
BMC Res Notes. 2023 Aug 7;16(1):164
pubmed: 37550734
Mol Ther Methods Clin Dev. 2016 Jan 27;3:15050
pubmed: 26858963
Expert Rev Vaccines. 2014 Dec;13(12):1501-21
pubmed: 25155825
Cancer Discov. 2011 Oct;1(5):408-19
pubmed: 22586631
J Biotechnol. 2016 Nov 20;238:1-8
pubmed: 27616621
J Med Virol. 2015 Dec;87(12):2098-105
pubmed: 26010580
Iran J Basic Med Sci. 2013 Aug;16(8):891-5
pubmed: 24106591